Loading...
Neuroprotective Activity of (-)-Epigallocatechin Gallate against Lipopolysaccharide-Mediated Cytotoxicity
Liu, Jin-Bao Zhou, Li Wang, Yi-Zhong Wang, Xu Ho, Wen-Zhe Li, Jie-Liang
Liu, Jin-Bao
Zhou, Li
Wang, Yi-Zhong
Wang, Xu
Ho, Wen-Zhe
Li, Jie-Liang
Citations
Altmetric:
Genre
Journal article
Date
2016-04-12
Advisor
Committee member
Group
Department
Pathology and Laboratory Medicine
Subject
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.1155/2016/4962351
Abstract
Lipopolysaccharide- (LPS-) mediated systemic inflammation plays a critical role in neurodegenerative diseases. The present study was conducted to evaluate the protective effects of epigallocatechin gallate (EGCG), the major component in green tea, on LPS-mediated inflammation and neurotoxicity. LPS treatment of macrophages induced expression of proinflammatory cytokines (TNF-α, IL-1β, and IL-6). However, EGCG pretreatment of macrophages significantly inhibited LPS-mediated induction of these cytokines. In addition, EGCG significantly diminished LPS-induced inflammatory cytokines in the peripheral mononuclear blood cells (PBMCs). Supernatant from EGCG-pretreated and LPS-activated macrophage cultures was found to be less cytotoxic to neurons than that from non-EGCG-pretreated and LPS-activated macrophage cultures. Furthermore, EGCG treatment of neurons could inhibit LPS-induced production of reactive oxygen species (ROS). Thus EGCG represents a potent and useful neuroprotective agent for inflammation-mediated neurological disorders.
Description
Citation
Jin-Biao Liu, Li Zhou, Yi-Zhong Wang, Xu Wang, Yu Zhou, Wen-Zhe Ho, Jie-Liang Li, "Neuroprotective Activity of ()-Epigallocatechin Gallate against Lipopolysaccharide-Mediated Cytotoxicity", Journal of Immunology Research, vol. 2016, Article ID 4962351, 10 pages, 2016. https://doi.org/10.1155/2016/4962351
Citation to related work
Hindawi
Has part
Journal of Immunology Research, Vol. 2016, Special Issue: Clinical and Experimental Immunomodulation 2016
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu